JP2000247873A - Composition for erasing sense of incompatibility at mucosal site - Google Patents
Composition for erasing sense of incompatibility at mucosal siteInfo
- Publication number
- JP2000247873A JP2000247873A JP11046466A JP4646699A JP2000247873A JP 2000247873 A JP2000247873 A JP 2000247873A JP 11046466 A JP11046466 A JP 11046466A JP 4646699 A JP4646699 A JP 4646699A JP 2000247873 A JP2000247873 A JP 2000247873A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- adult
- symptoms
- local anesthetic
- lidocaine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 10
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 10
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 9
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960004194 lidocaine Drugs 0.000 claims abstract description 7
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960002409 mepivacaine Drugs 0.000 claims abstract description 6
- 229960001747 cinchocaine Drugs 0.000 claims abstract description 5
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003889 eye drop Substances 0.000 claims description 4
- -1 streams Substances 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000007923 nasal drop Substances 0.000 claims description 2
- 229940100662 nasal drops Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 abstract description 11
- 210000003800 pharynx Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 7
- 244000269722 Thea sinensis Species 0.000 abstract description 4
- 244000299461 Theobroma cacao Species 0.000 abstract description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 abstract description 2
- XJKSTNDFUHDPQJ-UHFFFAOYSA-N 1,4-diphenylbenzene Chemical compound C1=CC=CC=C1C1=CC=C(C=2C=CC=CC=2)C=C1 XJKSTNDFUHDPQJ-UHFFFAOYSA-N 0.000 abstract description 2
- 240000007154 Coffea arabica Species 0.000 abstract description 2
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 abstract description 2
- 208000002193 Pain Diseases 0.000 abstract description 2
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 abstract description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 abstract description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 abstract description 2
- 235000001046 cacaotero Nutrition 0.000 abstract description 2
- 235000005487 catechin Nutrition 0.000 abstract description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 abstract description 2
- 229950001002 cianidanol Drugs 0.000 abstract description 2
- 235000016213 coffee Nutrition 0.000 abstract description 2
- 235000013353 coffee beverage Nutrition 0.000 abstract description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- 150000002989 phenols Chemical class 0.000 abstract description 2
- 235000020095 red wine Nutrition 0.000 abstract description 2
- 235000013616 tea Nutrition 0.000 abstract description 2
- 235000014620 theaflavin Nutrition 0.000 abstract description 2
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 abstract description 2
- 229940026509 theaflavin Drugs 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010041232 sneezing Diseases 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- ZRVSAJIGCDWADZ-UHFFFAOYSA-N Leucoanthocyanin Natural products OCC1OC(CC(O)C1O)OC2C(O)c3c(O)cc(O)cc3OC2c4ccc(O)c(O)c4 ZRVSAJIGCDWADZ-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102100031083 Uteroglobin Human genes 0.000 description 1
- 108090000203 Uteroglobin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000008376 breath freshener Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229920001461 hydrolysable tannin Polymers 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N isomenthone Natural products CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- FZHLWVUAICIIPW-UHFFFAOYSA-M sodium gallate Chemical compound [Na+].OC1=CC(C([O-])=O)=CC(O)=C1O FZHLWVUAICIIPW-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、咽頭部をはじめと
する粘膜部位の違和感の解消に有効な組成物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition effective for relieving discomfort in mucous membranes including the pharynx.
【０００２】[0002]
【従来の技術】風邪症候群は、ウイルスの感染により発
症するものと考えられているが、原因療法として有効な
抗ウイルス剤は未だ開発されておらず、専ら個々の風邪
症状の改善を目的とする対症療法を行うことが風邪治療
の中心となっている。2. Description of the Related Art The cold syndrome is thought to be caused by infection with a virus. However, no effective antiviral agent has been developed as a causative treatment, and it is aimed solely at improving individual cold symptoms. Performing symptomatic treatment is central to cold treatment.
【０００３】しかし、風邪症状が進行してしまった後で
は症状が複合的になり、対症療法の効果も緩慢なものに
なりがちであるため、いわゆる風邪の引きはじめに対処
することが重要である。[0003] However, after the cold symptoms have progressed, the symptoms tend to be complex and the effect of symptomatic treatment tends to be slow, so it is important to deal with the beginning of the so-called cold.
【０００４】ここで、風邪の初期症状としては、喉の痛
み、鼻がムズムズする、くしゃみ、目がしょぼしょぼす
るなど、粘膜部位に違和感を生じることが多い。このよ
うな粘膜部位の違和感は、そのほとんどが粘膜部位の充
血、腫脹、損傷などが原因であり、そのような違和感
は、新たなウイルス感染、細菌の二次感染などに暴露す
る機会をつくり出し、違和感の重症化や遷延化、全身症
状への拡大に結びつきやすい。したがって、粘膜部位の
違和感が生じる風邪の初期に、十分な対処をすることに
よって風邪症状の悪化を防止することが可能になる。[0004] The initial symptoms of a cold often cause discomfort in the mucous membrane region, such as sore throat, stuffy nose, sneezing, and drizzling eyes. Most of such discomfort in mucosal sites is caused by hyperemia, swelling, damage, etc. of mucosal sites, and such discomfort creates opportunities for exposure to new viral infections, secondary bacterial infections, etc. It is likely to lead to severe and prolonged discomfort and spread to systemic symptoms. Therefore, it is possible to prevent the cold symptoms from worsening by taking sufficient measures in the early stage of a cold in which the mucous membrane part is uncomfortable.
【０００５】従来、粘膜部位の違和感の改善には、殺菌
薬、消毒薬などをトローチ剤、ドロップ剤、スプレー剤
などで投与する方法が行われている。しかし、それらに
よる粘膜部位の違和感解消は一時的なものであり、粘膜
組織そのものの修復作用を有しないため、頻繁に投与し
なくてはならないなど煩雑である。その一方で、需要者
が購入しやすいのど飴などの需要が高まっているが、や
はり治療効果がないので一時的な違和感解消に過ぎな
い。[0005] Conventionally, in order to improve the sense of discomfort at the mucosal site, a method of administering a bactericide, a disinfectant, or the like using a troche, a drop, a spray, or the like has been performed. However, the elimination of discomfort at the mucosal site due to these is temporary, and does not have a repairing effect on the mucosal tissue itself. On the other hand, there is a growing demand for candy and the like, which are easy for consumers to purchase, but since it has no therapeutic effect, it is only a temporary relief of discomfort.
【０００６】したがって、粘膜部位の違和感を持続的に
解消することができる薬剤の開発が望まれていた。[0006] Therefore, there has been a demand for the development of a drug capable of continuously eliminating the discomfort of the mucosal site.
【０００７】ポリフェノール類は、茶などの中に多く含
まれていることが知られており、茶中のポリフェノール
が各種のウイルスや細菌の感染を防御することが知られ
ている（特許第２７２７４７１号、特開平３−１０６８
２０、特開平３−２４６２２７）。しかしながら、風邪
罹患後に粘膜部位の違和感を除去・軽減するような作用
は知られていない。[0007] It is known that polyphenols are contained in a large amount in tea and the like, and it is known that the polyphenol in tea protects against infections of various viruses and bacteria (Japanese Patent No. 2727471). JP-A-3-1068
20, JP-A-3-246227). However, there is no known effect of removing or reducing the discomfort at the mucosal site after a cold.
【０００８】[0008]
【発明が解決しようとする課題】本発明は、咽頭部、
鼻、目などの粘膜部位の違和感の除去または軽減を図る
のに有効な、使用感の優れた粘膜適用組成物を提供する
ことを目的とする。SUMMARY OF THE INVENTION The present invention provides a pharynx,
An object of the present invention is to provide a composition for mucosal application that is effective for removing or reducing discomfort in mucous membrane sites such as the nose and eyes, and has an excellent feeling in use.
【０００９】[0009]
【課題を解決するための手段】本発明者らは、課題を解
決すべく鋭意研究を重ねた結果、ポリフェノール類およ
び局所麻酔薬を配合した組成物には、咽頭部をはじめと
する粘膜部位の違和感の改善に著しい効果が有ることを
見出し本発明を完成した。Means for Solving the Problems The inventors of the present invention have conducted intensive studies to solve the problems, and as a result, a composition containing polyphenols and a local anesthetic has been added to a mucosal region such as the pharynx. The present inventor has found that there is a remarkable effect on improvement of discomfort, and completed the present invention.
【００１０】すなわち本発明は、ポリフェノール類およ
び局所麻酔薬からなる組成物である。That is, the present invention is a composition comprising a polyphenol and a local anesthetic.
【００１１】[0011]
【発明の実施の形態】本発明でポリフェノール類とは、
茶、コーヒー、カカオ、赤ワイン、チョコレートなどに
含まれる、１分子中に水酸基を２個以上含むフェノール
性化合物であり、具体的には加水分解型タンニン、縮合
型タンニン、ピロガロールタンニン、カテコールタンニ
ン、タンニン酸、カテキン、エピカテキン、ロイコアン
トシアニジン類、テアフラビン、リスベラトロールなど
があげられる。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, polyphenols are
A phenolic compound containing two or more hydroxyl groups in one molecule contained in tea, coffee, cacao, red wine, chocolate, etc., specifically, hydrolyzable tannin, condensed tannin, pyrogallol tannin, catechol tannin, tannin Acid, catechin, epicatechin, leucoanthocyanidins, theaflavin, resveratrol and the like.
【００１２】ポリフェノール類の配合量は、成人で一日
当たり２５０〜６０００mgが好ましく、５００〜５００
０mgがさらに好ましい。The compounding amount of the polyphenol is preferably 250 to 6000 mg per day for an adult, and 500 to 500 mg per day.
0 mg is more preferred.
【００１３】本発明で局所麻酔薬とは医薬品などで一般
的に用いられるものを使用することができるが、好まし
いものとしてリドカイン、ジブカイン、メピバカインお
よびそれらの塩類などをあげることができる。In the present invention, as the local anesthetic, those generally used in pharmaceuticals and the like can be used. Preferred examples thereof include lidocaine, dibucaine, mepivacaine and salts thereof.
【００１４】本発明において、局所麻酔薬は通常医薬品
に配合可能な量を配合することができる。具体的には１
日量でリドカインは３〜７５mg、好ましくは５〜６０mg
であり、ジブカインは１〜１５mg、好ましくは２〜１０
mgであり、メピバカインは１．５〜２０mg、好ましくは
２．５〜１５mgである。この投薬量は年齢、体重、病状
により適宜増減することができる。In the present invention, the local anesthetic can be added in an amount which can be usually added to a medicine. Specifically 1
Lidocaine 3 to 75 mg, preferably 5 to 60 mg daily
And 1 to 15 mg of dibucaine, preferably 2 to 10
mg, and mepivacaine is 1.5 to 20 mg, preferably 2.5 to 15 mg. This dosage can be appropriately increased or decreased depending on the age, weight, and medical condition.
【００１５】本発明の組成物が有効な粘膜部位とは、咽
頭、鼻、目などの風邪の初期症状が起こりやすい部位で
あり、症状としては、のどあれ、声がれ、のどの不快
感、のどの痛み、のどのはれ、くしゃみ、鼻みず、鼻づ
まり、目の疲れ、目のかすみ、結膜充血などの症状のこ
とである。The mucosal site where the composition of the present invention is effective is a site where the initial symptoms of a cold such as the pharynx, nose and eyes are likely to occur, and the symptoms include throat, voice, throat discomfort, Sore throat, sore throat, sneezing, nasal stuffiness, nasal congestion, eye fatigue, blurred eyes, conjunctival congestion, etc.
【００１６】本発明の組成物は、必要に応じて他の薬効
成分、賦形剤、滑沢剤、崩壊剤、界面活性剤、溶解補助
剤、緩衝剤、保存剤、香料、色素、甘味剤・嬌味剤、清
涼化剤、着色剤などを使用して、常法により、トローチ
剤、ドロップ剤、舐剤、口腔内溶解剤、ストリーム剤、
スプレー剤、含嗽剤、点鼻薬、洗鼻薬、点眼剤などに調
製することができる。The composition of the present invention may contain, if necessary, other active ingredients, excipients, lubricants, disintegrants, surfactants, solubilizers, buffers, preservatives, flavors, pigments, sweeteners. -Using lozenges, fresheners, coloring agents, etc., in the usual manner, troches, drops, licks, oral dissolving agents, stream agents,
It can be prepared into sprays, mouthwashes, nasal drops, nasal washes, eye drops and the like.
【００１７】本発明の組成物は、風邪薬、鎮咳去痰薬、
鼻炎用薬、咽喉頭用薬、風邪予防薬、口腔内殺菌用薬、
口腔内消炎薬、口臭除去薬、点眼薬などに用いることが
できる。The composition of the present invention comprises a cold medicine, an antitussive expectorant,
Rhinitis medicine, pharyngolaryngeal medicine, cold prevention medicine, oral disinfectant medicine,
It can be used as an antiphlogistic for oral cavity, a breath freshener, an eye drop, and the like.
【００１８】[0018]
【発明の効果】本発明により、咽頭部をはじめとする粘
膜部位の疼痛症状（のどの痛み）をはじめとする幅広い
違和感に対する改善効果が著しく向上した粘膜部位用組
成物を提供することが可能になった。Industrial Applicability According to the present invention, it is possible to provide a composition for a mucous membrane part in which the effect of improving a wide variety of discomfort including pain symptoms (throat pain) of the mucous membrane part including the pharynx is significantly improved. became.
【００１９】[0019]
【実施例】以下、実施例および試験例により本発明をさ
らに詳細に説明する。The present invention will be described in more detail with reference to the following Examples and Test Examples.
【００２０】実施例 表１に示した処方をグリセリン４mlおよび精製水で全量
２０mlにして溶解させ、実施例１〜６および比較例１〜
６をストリーム剤として製した。Examples The formulations shown in Table 1 were dissolved in 4 ml of glycerin and purified water to make a total volume of 20 ml.
No. 6 was prepared as a stream agent.
【００２１】試験例 実施例１〜６および比較例１〜６を、咽頭部に違和感を
感じる風邪症候群患者に対し１群５名ずつで、１日６回
３日間使用させ、使用前後の咽頭部の症状をアンケート
形式で回答させた。なお、症状は「５点：非常に耐えら
れない違和感を感じる」「４点：非常に違和感を感じ
る」「３点：違和感を感じる」「２点：軽度の違和感を
感じる」「１点：わずかに違和感を感じる」「０点：ま
ったく違和感を感じない」の６段階で評価し、投与後に
２点以上点数が減った者を有効と判定した。有効人数お
よび有効率を表１に示した。Test Examples Examples 1 to 6 and Comparative Examples 1 to 6 were used by a group of five patients with cold sensation who felt discomfort in the pharynx six times a day for three days. The symptoms were answered in a questionnaire format. Symptoms are “5 points: I feel very intolerable”, “4 points: I feel very uncomfortable”, “3 points: I feel uncomfortable”, “2 points: I feel a slight discomfort”, “1 point: Slight” The subjects were evaluated on a 6-point scale of “I feel uncomfortable”, “0 point: I do not feel any discomfort”, and those who lost 2 or more points after administration were judged to be effective. Table 1 shows the effective number of persons and the effective rate.
【００２２】[0022]
【表１】 配合量および有効率 （１日量；ｍｇ） [Table 1] Compounding amount and effective rate (daily dose; mg)
【００２３】実施例７ 下記の各成分及び分量を秤量し均一に混合した後、得ら
れた混合粉末を直打法により１剤重量３００mgになるよ
うに打錠し、トローチ剤を得た。Example 7 After the following components and amounts were weighed and uniformly mixed, the resulting mixed powder was tableted by a direct compression method so that one tablet weighed 300 mg to obtain a troche.
【００２４】 タンニン酸 ２０００ｇ リドカイン ５０ｇ 塩酸クロルヘキシジン １５ｇ 塩化リゾチーム ３０ｇ（力価） 乳糖 １５０ｇ 低置換度ヒドロキシプロピルセルロース １２５ｇ ステアリン酸マグネシウム １５ｇ 硬化ヒマシ油 １５ｇ。Tannic acid 2000 g Lidocaine 50 g Chlorhexidine hydrochloride 15 g Lysozyme chloride 30 g (titer) Lactose 150 g Low-substituted hydroxypropylcellulose 125 g Magnesium stearate 15 g Hardened castor oil 15 g
【００２５】実施例８下記の各成分及び分量を秤量し均
一に混合した後、水飴と練り合わせ舐剤２６００ｇを得
た。Example 8 The following components and amounts were weighed and uniformly mixed, and 2600 g of a syrup mixed with starch syrup was obtained.
【００２６】 エピガロカテキン １５００ｇ リドカイン ６０ｇ 塩化セチルピリジニウム ３ｇ 塩化リゾチーム ３０ｇ（力価） 乳糖 １２０ｇ 低置換度ヒドロキシプロピルセルロース １００ｇ ステアリン酸マグネシウム １５ｇ 水飴 ７７２ｇ。Epigallocatechin 1500 g Lidocaine 60 g Cetylpyridinium chloride 3 g Lysozyme chloride 30 g (titer) Lactose 120 g Low-substituted hydroxypropylcellulose 100 g Magnesium stearate 15 g Water syrup 772 g.
【００２７】実施例９下記の各成分及び分量を秤量し均
一に混合した後、精製水１００ｍｌに溶解し洗鼻薬を製
した。Example 9 The following components and amounts were weighed and uniformly mixed, and then dissolved in 100 ml of purified water to prepare a nasal rinse.
【００２８】 ロイコアントシアニン ５０００mg メピバカイン １０mg 塩化セチルピリジニウム ６mg 塩酸リドカイン ５００mg dl−メントール ５００mg。Leucoanthocyanin 5000 mg Mepivacaine 10 mg Cetylpyridinium chloride 6 mg Lidocaine hydrochloride 500 mg dl-Menthol 500 mg.
【００２９】実施例１０ 下記の各成分及び分量を秤量し均一に混合した後、精製
水１００ｍｌに溶解し点眼剤を製した。Example 10 The following components and amounts were weighed and uniformly mixed, and then dissolved in 100 ml of purified water to prepare eye drops.
【００３０】 没食子酸ナトリウム ４５００mg 塩酸ジブカイン １０mg 塩化デカリニウム １．５mg 塩化リゾチーム ４５mg（力価） 塩酸リドカイン ５００ｍｇSodium gallate 4500 mg dibucaine hydrochloride 10 mg decalinium chloride 1.5 mg lysozyme chloride 45 mg (titer) lidocaine hydrochloride 500 mg
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｐ 11/00 Ａ６１Ｋ 31/00 ６１１ 43/00 ６４３ Ａ６１Ｋ 31/167 31/165 ６０２ 31/445 31/445 31/47 31/47 Ｆターム(参考） 4C076 AA12 AA24 AA49 BB01 BB22 BB24 BB25 CC01 CC10 CC35 DD38 FF15 4C086 AA02 BC21 BC28 MA02 MA03 MA04 MA13 MA17 MA35 MA52 MA57 MA58 MA59 NA14 ZA21 ZA33 ZA34 ZA59 ZB33 4C206 AA02 CA19 CA20 FA31 MA02 MA03 MA04 MA33 MA37 MA55 MA72 MA77 MA78 MA79 NA14 ZA21 ZA33 ZA34 ZA59 ZB33──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61P 11/00 A61K 31/00 611 43/00643 A61K 31/167 31/165 602 31/445 31/445 31/47 31/47 F-term (reference) 4C076 AA12 AA24 AA49 BB01 BB22 BB24 BB25 CC01 CC10 CC35 DD38 FF15 4C086 AA02 BC21 BC28 MA02 MA03 MA04 MA13 MA17 MA35 MA52 MA57 MA58 MA59 NA14 ZA21 ZA33 ZA34 ZA59 ZB33 CA4CA MA03 MA04 MA33 MA37 MA55 MA72 MA77 MA78 MA79 NA14 ZA21 ZA33 ZA34 ZA59 ZB33
Claims (4)
なる組成物。1. A composition comprising a polyphenol and a local anesthetic.
なる粘膜部位用組成物。2. A composition for a mucosal site comprising a polyphenol and a local anesthetic.
メピバカインおよびそれらの塩類から選ばれる１種また
は２種以上である請求項１または２に記載の組成物。3. The local anesthetic is lidocaine, dibucaine,
3. The composition according to claim 1, wherein the composition is one or more selected from mepivacaine and salts thereof.
溶解剤、ストリーム剤、スプレー剤、含嗽剤、点鼻薬、
洗鼻薬および点眼剤から選ばれるいずれかの形態である
請求項１〜３のいずれかに記載の組成物。4. Lozenges, drops, lozenges, oral dissolving agents, streams, sprays, gargles, nasal drops,
The composition according to any one of claims 1 to 3, which is in any form selected from a nasal wash and an eye drop.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11046466A JP2000247873A (en) | 1999-02-24 | 1999-02-24 | Composition for erasing sense of incompatibility at mucosal site |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11046466A JP2000247873A (en) | 1999-02-24 | 1999-02-24 | Composition for erasing sense of incompatibility at mucosal site |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2000247873A true JP2000247873A (en) | 2000-09-12 |
Family
ID=12747958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11046466A Pending JP2000247873A (en) | 1999-02-24 | 1999-02-24 | Composition for erasing sense of incompatibility at mucosal site |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2000247873A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002326941A (en) * | 2001-05-01 | 2002-11-15 | Naomasa Morita | Agent for ophthalmic use |
| FR2927256A1 (en) * | 2008-02-13 | 2009-08-14 | Top Pharm Sarl Lab | Composition, useful for treating inflammatory disease of respiratory track, comprises alpha-amylase enzyme and local anesthetic |
| WO2014038593A3 (en) * | 2012-09-05 | 2014-05-01 | テイカ製薬株式会社 | Granulated material for tablet that rapidly disintegrates in mouth |
-
1999
- 1999-02-24 JP JP11046466A patent/JP2000247873A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002326941A (en) * | 2001-05-01 | 2002-11-15 | Naomasa Morita | Agent for ophthalmic use |
| FR2927256A1 (en) * | 2008-02-13 | 2009-08-14 | Top Pharm Sarl Lab | Composition, useful for treating inflammatory disease of respiratory track, comprises alpha-amylase enzyme and local anesthetic |
| WO2014038593A3 (en) * | 2012-09-05 | 2014-05-01 | テイカ製薬株式会社 | Granulated material for tablet that rapidly disintegrates in mouth |
| US9463165B2 (en) | 2012-09-05 | 2016-10-11 | Teika Pharmaceutical Co., Ltd. | Granular material for orally fast disintegrating tablets |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8450339B2 (en) | Compositions for treatment of common cold | |
| US6165494A (en) | Iodine-containing nasal moisturizing saline and mouthwash solutions | |
| JP6768733B2 (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
| Godfrey et al. | Zinc gluconate and the common cold: a controlled clinical study | |
| US6171611B1 (en) | Iodine-containing nasal moisturizing saline and mouthwash solutions | |
| EP0381522A1 (en) | Spray preparations for respiratory tract infections | |
| GB2430623A (en) | Medicaments for treating chronic respiratory disease | |
| KR20090096598A (en) | Antiviral composition and method of use | |
| WO2021184070A1 (en) | Antiviral composition for oral care | |
| NO309965B1 (en) | Oral pharmaceutical anti-cough preparation | |
| JP2000247873A (en) | Composition for erasing sense of incompatibility at mucosal site | |
| JP2002205942A (en) | Composition for topical application | |
| JP2000109428A (en) | Composition for pharyngeal mucosa | |
| Stübner et al. | Efficacy and Safety of an Oral Formulation of Cetirizine and Prolonged-release Pseudoephedrine versus Xylometazolin Nasal Spray in Nasal Congestion | |
| JPH11228387A (en) | Medicinal composition containing iodine-based antimicrobial agent | |
| IL110780A (en) | Pharmaceutical compositions containing 1, 3-bis (2-carboxy-chromon-5-yloxy)-propan -2-ol for the treatment of the common cold | |
| JP2002241310A (en) | Locally applying composition | |
| JP2000327573A (en) | Composition for applying to mucosa | |
| JP2006008540A (en) | Cold remedy | |
| US20100203166A1 (en) | Methods of preventing respiratory infections | |
| JP2001139465A (en) | Composition for pharyngeal mucosa | |
| JP2003342186A (en) | Oral liquid formulation composition for rhinitis | |
| JP2002145764A (en) | Composition for pharyngeal mucous membrane | |
| JP2002370977A (en) | Composition for topical application | |
| AU2002329578B2 (en) | Compositions for treatment of common cold |